BioSig Technologies, Inc. (BSGM)
NASDAQ: BSGM · IEX Real-Time Price · USD
1.300
-0.020 (-1.52%)
At close: Apr 25, 2024, 4:00 PM
1.170
-0.130 (-10.00%)
Pre-market: Apr 26, 2024, 4:42 AM EDT

Company Description

BioSig Technologies, Inc., together with its subsidiaries, a medical device company, commercializes advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias.

The company offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.

It also focuses on enhancing intracardiac signal acquisition and diagnostic information for catheter ablation procedures for arrhythmias.

The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems.

BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

BioSig Technologies, Inc.
BioSig Technologies logo
Country United States
Founded 2009
Industry Medical Devices
Sector Healthcare
Employees 4
CEO Frederick D. Hrkac

Contact Details

Address:
55 Greens Farms Road
Westport, Connecticut 06880
United States
Phone (203) 409-5444
Website biosig.com

Stock Details

Ticker Symbol BSGM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001530766
CUSIP Number 09073N201
ISIN Number US09073N3008
Employer ID 26-4333375
SIC Code 3845

Key Executives

Name Position
Frederick D. Hrkac President, Principal Executive Officer and Executive Vice President
Dr. Budimir S. Drakulic Ph.D. Chief Scientist
Andrew Gornell Ballou Vice President of Investor Relations

Latest SEC Filings

Date Type Title
Apr 16, 2024 10-K Annual Report
Apr 2, 2024 NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Mar 18, 2024 8-K Current Report
Mar 12, 2024 8-K Current Report
Mar 11, 2024 144 Filing
Mar 11, 2024 8-K Current Report
Feb 28, 2024 8-K Current Report
Feb 21, 2024 8-K Current Report
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 6, 2024 8-K Current Report